Xu Qing from Yuanhe Chencun: The Core Value of Fund-of-Funds in the New Environment

2020-09-10

On September 9, 2020, Xu Qing, Managing Partner at Yuanhe Chukun, attended the 2020 China Fund of Funds Summit and the 2nd Lujiang Venture Capital Forum, delivering a keynote speech.

Yuanhe Chencun Welcomes Three Companies, Including Shengxiang Bio, to the Stock Market

2020-08-28

On August 28, 2020, three companies within the fund-of-funds portfolio managed by Yuanhe Chukun simultaneously listed on exchanges in China and the U.S. Two of these companies were listed on China's STAR Market: Shengxiang Biotechnology Co., Ltd. (referred to as "Shengxiang Bio," stock code "688289.SH").

The first batch of companies listed under the registration-based system on the ChiNext Board—Yuanhe Chencun successfully secured investments in 3 of them.

2020-08-24

On August 24, 2020, the ChiNext board marked a historic milestone as the first batch of 18 companies listed under the registration-based system. Among these initial 18 companies, three were portfolio investments managed by Yuanhe Chencun’s fund-of-funds.

Yuanhe Chencun reaps a bountiful IPO harvest—Yirui Optoelectronics, CanSinoBio, and others successfully pass review.

2020-07-17

In the past month, eight companies from the mother fund portfolio managed by Yuanhe Chencun successfully passed their review sessions: six on the STAR Market, and one each on the ChiNext and SME boards. Notably, Meichang New Materials is expected to become one of the first batch of companies listed under the centralized registration system following the STAR Market's reform.

Yuanhe Chencun Reaps Frequent Good News—Qixinxin, Shengxiang Bio, and Genshengzi Successfully Pass Review

2020-06-24

Recently, three companies from the fund-of-funds portfolio managed by Yuanhe Chencun successfully passed their review processes.

Yuanhe Chencun Helps Peijia Medical Go Public

2020-05-15

On May 15, 2020, Peijia Medical (9996.HK), part of the mother fund portfolio managed by Yuanhe Chukun, successfully launched its IPO, becoming the first high-end medical device company to list on the Hong Kong Stock Exchange in 2020.